Kidney Disease & Nephrology Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Mechanism of SGLT2 Inhibition in the Kidney

This Phase 4 trial from the University of Michigan is exploring how SGLT2 inhibitors, such as Canagliflozin, affect kidney function in adults with type 2 diabetes and diabetic kidney disease. The goal is to see if these medications can help protect the kidneys and improve treatment for people living with these conditions. The study is currently recruiting adults aged 18 to 80 in the United States, offering hope for better kidney health management in diabetes.

Safety of Short-course of NSAIDs in Pediatric Patients With CKD

Researchers at the University of Colorado, Denver are investigating the safety of short-term use of NSAIDs, commonly used pain relievers, in children with chronic kidney disease after surgery. This Phase 4 trial aims to determine whether these medications increase the risk of kidney injury in young patients. The findings could lead to safer pain management strategies for children with mild-to-moderate chronic kidney disease, improving recovery and quality of care.

Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.

This completed Phase 4 trial conducted by the University Hospital in Strasbourg, France, studied whether intravenous immunoglobulin treatment can prevent BK virus infection in kidney transplant recipients who have low antibody levels before transplantation. Preventing this viral infection is important because it can cause complications and even lead to loss of the transplanted kidney. The results could help protect transplant patients from serious infections and improve long-term transplant success.

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

The University Health Network in Toronto completed a Phase 3 trial testing dapagliflozin, an SGLT2 inhibitor, in kidney transplant recipients with or without diabetes. The study looked at whether this drug could lower blood pressure, a common issue after transplant, potentially reducing complications. Positive results may offer a new treatment option to improve the health and wellbeing of people living with a kidney transplant.

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Johns Hopkins University is recruiting participants for a study examining kidney transplants from donors with HIV to recipients who also have HIV. This research aims to understand the risk of organ rejection and long-term health outcomes in this group. Expanding donor options could increase access to life-saving transplants for people living with HIV and kidney failure.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.